Biocon slips 4% despite arm denying bribery charges

At 10:26 AM, the stock of Biocon was down 3 per cent at Rs 316.10, as compared to 1 per cent decline in the S&P BSE Sensex

Biocon Biologics, Serum Institute Life Sciences enter strategic alliance
Premium

SI Reporter Mumbai
Shares of Biocon were down 4 per cent to Rs 312.55 on the BSE in Wednesday’s intra-day trade despite Biocon Biologics denying allegations of bribery against the company and its officials associated with the approval process of one of its products in India. Biocon Biologics, a subsidiary of Biocon, is a unique, fully integrated global biosimilars organization.

"We strongly condemn any acts of corruption and violation of rules by way of offering or paying bribes or undue favours, either directly or indirectly. We adopt global best practices in corporate governance and business responsibility," Biocon Biologics said in a statement.

Don't miss the most important news and views of the day. Get them on our Telegram channel

First Published: Jun 22 2022 | 10:48 AM IST

Explore News

To read the full story, subscribe to BS Premium now, at just Rs 249/ month.

Key stories on business-standard.com are available only to BS Premium subscribers.

Register to read more on Business-Standard.com